To date some 30 DNA-drug complexes have been solved, using synthetic deoxyolignucleotides of length between 6 and 12 base pair units. The drugs divide into three main categories: molecules which bind in the minor grove of DNA, molecules which both intercalate between the base pairs and bind to the minor grove and bifunctional intercalators. There are determinations of the same drug binding to different base sequences, and the same base sequences interacting with drug molecules which have been modified chemically in small but significant ways. By comparing the different structures it is possible to determine changes in both the drug and the DNA molecules on complex formation, the types of forces which are involved in the interactions and possibly put forward some suggestions for modifying the drug molecules so as to make them more specific for certain base sequences. The paper gives a brief overview of the field.
INTRODUCTION
DNA is a natural product, indeed the natural product of the paramount importance in understanding the mechanism of genetic processes, of cell growth and diffrentiation, of ageing and senescence. It is also a logical target for chemotherapy. Binding of peptides, small organic and inorganic molecules to DNA can interfere with the numerous processes, including transcription and replication in which DNA participates. Such interference can retard or prevent cell growth. Extensive chemical and biochemical studies have characterised a variety of molecules of this type and numerous antiviral, antibiotical. antiprotozoal and antitumour agents have been identified. Some of these have clinical applications, others are under clinical trial.
The development of methods of deoxyoligonucleotide synthesis in the early 1970s has made it possible to investigate details of the structure of DNA at a molecular level by X-ray crystallographic and N M R studies.
(for a review of X-ray structures see refs 1 and 2). The X-ray studies, carried out at resolutions of between 1.2 and 2.5 A, gave a wealth of information about the conformational variability and flexibility of DNA, the influence of base sequence and the role of water and counterions. The challenge now is to obtain similar information about drug-DNA complexes. The hope is that such studies will lead to rules governing sequence specific binding and an insight into the correlation between DNA structure, sequence and activity. Such information is evidently important for rational drug design (ref. 3) and may well lead to the development of more potent antibiotics and antitumour agents. One must, however, beware of too simplistic a reliance on structural information and on molecular modelling studies. The delivery of a drug to the target site, and only the target site, is a complex problem which calls for solution studies, biological experiments and different types of insight into design requirements.
The X-ray structure analysis of DNA drug complexes made a relatively slow start. Up to 1984 the structure of only one complex was published, as a preliminary report (ref. 4) , but increasingly more complexes have been solved. Progress has been particularly rapid in the past four years and currently some 30 complexes have been characterised. There have been studies of the same drug complexed to two different deoxyoligonucleotide sequences and the same deoxyoligonucleotide sequence complexed to a series of molecules obtained by subtle chemical modifications of a particular drug. Such comparative studies offer the best hope of understanding the principles of DNA drug recognition and the mutual influence of the two components on complexation. 
EXPERIMENTAL CONSIDERATIONS
The X-ray investigations discussed in this paper all refer to single crystal X-ray analyses, which are critically dependent on the preparation of diffraction quality crystals. The starting materials are relatively readily obtained. The deoxyoligonucleotides are synthesised by standard solid phase techniques (ref. 5 ) 
